Pemtumomab

Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]

Pemtumomab
Monoclonal antibody
Type?
SourceMouse
TargetMUC1
Clinical data
Trade namesTheragyn
Routes of
administration
Intraperitoneal
ATC code
  • none
Identifiers
ChemSpider
  • none
 NY (what is this?)  (verify)

It has been granted orphan drug status in Europe.[3]

References

  1. Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524.
  2. ClinicalTrials.gov
  3. Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.